Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Oslo - Delayed Quote NOK

Aker BioMarine ASA (AKBM.OL)

Compare
52.00
-1.00
(-1.89%)
At close: April 16 at 1:05:03 PM GMT+2

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in NOK.
NameTitlePayExercisedYear Born
Mr. Matts Johansen Chief Executive Officer 11.18M -- 1976
Ms. Katrine Mourud Klaveness Chief Financial Officer 8.52M -- 1977
Ms. Hege Spaun Chief Officer People & Communication 4.06M -- --
Mr. Trond Atle Smedsrud Chief Executive Officer of Emerging Business 4.26M -- --
Mr. Simon Seward Chief Executive Officer of Human Health Ingredients 5.09M -- --
Mr. Seth French Chief Executive Officer of Lang Pharma Nutrition Inc 5.83M -- --
Christopher Robin Vinter Vice President of IR & Corporate Finance -- -- --
Ms. Tone Lorentzen Chief Operating Officer of Human Health Ingredients 3.62M -- --
Ms. Lise Wiger Financial Controller -- -- --
Anniken Færgestad Vice President of Finance -- -- --

Aker BioMarine ASA

Oksenøyveien 10
P.O. Box 496
Lysaker, 1327
Norway
47 24 13 00 00 https://www.akerbiomarine.com
Industry: 
Packaged Foods
Full Time Employees: 
249

Description

Aker BioMarine ASA, a biotech innovator, develops and supplies krill-derived products for consumer health and wellness worldwide. It operates through three segments: Human Health Ingredients (HHI), Consumer Health Products, and Emerging Business. The Human Health Ingredients segment sells B2B krill oil supplements for humans under the Superba Krill brand; supplements for brain health under the LYSOVETA brand; and marine-origin DHA omega-3 from microalgae under the Revervia brand name, as well as advanced phospholipid technology under PL+ name. The Consumer Health Products segment sells processed and packaged krill, fish, and plants derived raw materials to retailers in the United States. The Emerging Business segment offers krill oil under Kori brand name. The company provides protein solutions under the Understory brand; biostimulants under KRBNX brand; and a therapeutic candidate based on omega-3 to manage and treat cardiometabolic diseases under CaPre brand name, as well as delivers circular products utilizing recycled industrial and marine plastic waste under AION name. Aker BioMarine ASA was founded in 2006 and is headquartered in Lysaker, Norway. Aker BioMarine ASA is a subsidiary of Aker ASA.

Corporate Governance

Aker BioMarine ASA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

April 30, 2025 at 10:59 AM UTC

Aker BioMarine ASA Earnings Date

Recent Events

September 9, 2024 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers